Mirtazapine in combination;Mirtazapina en combinación

Actas Espanolas de Psiquiatria

Volumn 38, Issue 2, 2010, Pages 121-128

  Alvarez, Enríe ^a   Vinas F ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

Antidepressants; Depression; Mirtazapine

Indexed keywords

MIANSERIN; MIRTAZAPINE; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DEPRESSION; DRUG POTENTIATION; HUMAN; METABOLISM; PROCEDURES;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MIANSERIN; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 79952256452     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004;420(Suppl.) : 21-27.
2. Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006;26(1):75-78. (Pubitemid 43167095)
3. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63(4):424-34.
4. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. STAR'D Study Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354(12):1231-42.
5. Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, et al. The costs and benefits of enhanced depression care to employers. Arch Gen Psychiatry 2006;63(12):1345-53. (Pubitemid 44883167)
6. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 1993;14(7):262. (Pubitemid 23204242)
7. Gardier AM, Malagié I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergie antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 1996;10(1):16-27.
8. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. Serotonin autoreceptor function and antidepressant drug action. Psychopharmacol 2000;14(2):177-85. (Pubitemid 30389492)
9. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 2001;62(Suppl. 15) : 12-17. (Pubitemid 32601343)
10. Artigas F, Celada P, Laruelle M, Adell A. How does pindolol improve antidepressant action? Trends Pharmacol Sci 2001;22(5):224-8. (Pubitemid 32411522)
11. Artigas F, Pérez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51(3):248-51. (Pubitemid 24081512)
12. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349(9065):1594-7. (Pubitemid 27229140)
13. Isaac MT, Isaac MB, Gallo F, Tournoux A. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. Hum Psychopharmacol 2003;18(8):595-601. (Pubitemid 38028786)
14. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63(11):1217-23. (Pubitemid 44708080)
15. Portella MJ, de Diego-Adeliño J, Puigdemont D, Pérez-Egea R, Alvarez E, Artigas F, Pérez V. Pindolol augmentation enhances response outcomes in first depressive episodes. Eur Neuropsychopharmacol 2009;19(7):516-9.
16. Pérez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999;56(4):375-9. (Pubitemid 29165184)
17. Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 2004;65(2):238-43.
18. García-Sevilla JA, Udina C, Fuster MJ, Alvarez E, Casas M. Enhanced binding of [3H] (-) adrenaline to platelets of depressed patients with melancholia: effect of longterm clomipramine treatment. Acta Psychiatr Scand 1987;75(2):150-7. (Pubitemid 17025196)
19. García-Sevilla JA, Ventayol P, Pérez V, Rubovszky G, Puigdemont D, Ferrer-Alcón M, et al. Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 2004;29(3):580-8. (Pubitemid 38365935)
20. González-Maeso J, Rodríguez-Puertas R, Meana JJ, García-Sevilla JA, Guimón J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha (2A)-adrenoceptors. Mol Psychiatry 2002;7(7):755-67. (Pubitemid 34984953)
21. Beyer CE, Lin Q, Rosenzweig-Lipson S, Schechter LE. Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine. Eur J Pharmacol 2006;539(3):164-7. (Pubitemid 43783525)
22. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and longterm actions of mirtazapine. Int Clin Psychopharmacol 1995;10(Suppl 4) : 11-17. (Pubitemid 26058316)
23. Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998;51(3):255-66. (Pubitemid 29202174)
24. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57(4):607-31. (Pubitemid 29196924)
25. Klein DF, Davis JM. The drug treatment of depression. JAMA 1970;212(11):1962-3.
26. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157(9):1501-4.
27. Rubio G, San L, López-Muñoz F, Alamo C. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J Affect Disord 2004;81(1):67-72. (Pubitemid 38759329)
28. Carpenter LL, Yasmin S, Price LH. A double-blind, placebocontrolled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51(2):183-8. (Pubitemid 34127908)
29. Hannan N, Hamzah Z, Akinpeloye HO, Meagher D. Venlafaxinemirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol 2007;21(2):161-4. (Pubitemid 46280465)
30. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999;14(6):329-37. (Pubitemid 29531381)
31. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ; Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005;19(2):137-46. (Pubitemid 40321765)
32. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H, Vester-Blokland ED. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23(4):358-64. (Pubitemid 36951177)
33. Benkert, O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61(9):656-63.
34. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr; Mirtazapine vs. Paroxetine. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10(5):541-50. (Pubitemid 34984390)
35. Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006;26(1):75-8. (Pubitemid 43167095)
36. Guelfi JD, Ansseau M, Timmerman L, Karsgaard S; Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21(4):425-31. (Pubitemid 32673032)
37. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60(Suppl 17) : 18-22. (Pubitemid 29386035)
38. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62(5):358-61. (Pubitemid 32545558)
39. Winokur A, De Martinis NA 3rd, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64(10):1224-9.
40. Aapro M. 5-HT (3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005;69(2):97-109. (Pubitemid 41376907)
41. Amstislavskaya TG, Popova NK. The roles of different types of serotonin receptors in activation of the hypophyseal-testicular complex induced in mice by the presence of a female. Neurosci Behav Physiol 2004;34(8):833-7. (Pubitemid 39158082)
42. Ozmenler NK, Karlidere T, Bozkurt A, Yetkin S, Doruk A, Sutcigil L, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 2008;23(4):321-6. (Pubitemid 351982669)
43. Ravindran LN, Eisfeld BS, Kennedy SH. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. J Clin Psychopharmacol 2008;28(1):107-8.
44. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lechner-Schoner T, Strauss R, Engl J, et al. Effect of mirtazapine treatment on body composition and metabolism. Clin Psychiatry 2006;67(3):421-4.
45. Lee HY, Kang RH, Paik JW, Jeong YJ, Chang HS, Han SW, et al. Association of the adrenergic alpha 2a receptor-1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Res 2009;1262:1-6.
46. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000;28(10):1168-75.
47. Cozza KL, Armstrong SC. The Cytochrome P450 System. Drug Interactions Priciples for Medical Practice. Washington: American Psychiatric Publishing Inc., 2001.
48. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60(1):45-9. (Pubitemid 29069886)
49. Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust N Z J Psychiatry 2008;42(4):346-9. (Pubitemid 351386496)
50. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19(7):457-65.